Our scientific and clinical findings have been presented and published in prestigious peer-reviewed forums, and a selection of these have been curated for reference.
TLR Biology vaccine
|Date||Program||Title of Publication|
|APR 2016||TLR Biology vaccine||
Optimization, Production, and Characterization of a CpGOligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen
Bioconjugate Chemistry, 2016, 27, 1293−1304, DOI: 10.1021/acs.bioconjchem.6b00107
|DEC 2015||TLR Biology vaccine||
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys
The Journal of Immunology, 2016; 196:284-297; Prepublished online 25 November 2015; doi: 10.4049/jimmunol.1501903
|JUL 2011||TLR Biology||
Assessing the safety of adjuvanted vaccines.
Sci. Transl. Med., 2011; 3(93):93rv2.
|FEB 2011||TLR Biology||
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.
Immunity, 2011; 34(3):375-384.
|OCT 2010||TLR Biology||
Vaccine adjuvants: putting innate immunity to work.
Immunity, 2010; 33(4):492-503.
|AUG 2009||TLR Biology||
CpG-containing immunostimulatory DNA sequences elicit TNF-α–dependent toxicity in rodents but not in humans.
J. Clin. Invest., 2009; 119(9):2564–2576.
|JAN 2009||TLR Biology||
Signalling pathways leading to IFN-a production in human PDC and the possible use of agonists or antagonists of TLR-7 and TLR-9 in clinical indications (Review).
J. Intern. Med., 2009; 265:43-57.
|MAY 2007||TLR Biology||
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
Nature Medicine, 2007; 13(5):552-559.
|SEP 2006||TLR Biology||
Toll-like Receptor Recognition Regulates Immunodominance in an Antimicrobial CD4+ T Cell Response.
Immunity, 2006; 25:665-664.
|AUG 2006||TLR Biology||
Properties Regulating the Nature of the Plasmacytoid Dendritic Cell Response to TLR9 Activation.
J. Exp. Med., 2006; 203(8):1999-2008.
|JAN 2006||TLR Biology||
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Vaccine, 2006; 24(1): 20-26.
|FEB 2005||TLR Biology||
Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species.
DNA Cell Biol., 2005; 24(2):63-72.
|AUG 2004||TLR Biology||
CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.
J. Immunol., 2004; 173(3):1647-1657.
|JUN 2004||TLR Biology||
Polymyxin B enhances ISS-mediated immune responses across multiple species.
Cell. Immunol., 2004; 229(2):93-105.